Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Saliva Diagnostics (SALV) -- Ignore unavailable to you. Want to Upgrade?

To: rl who wrote (2032)	2/5/1998 7:09:00 PM
From: Shadow	Respond to of 3369

RL I agree with you completely reguarding approvals for sale in places like Romania and Kenya. They need the product, but its not likely they can pay for it. Reguarding the packaging issue. The Singapore plant manufactured the actual product while the sterile packaging was done by an outside vendor. The costs became prohibitive. The deal with UK/Wesley delivers a manufactured and packaged product ready for shipping. Packaging seems like a trivial issue, but when you are dealing with hundreds of thousands of units the hassles and costs can mount quickly. I agree with you 1000% reguarding reverse splits, management stock options and new private placements. I don't know what the answer is but I don;t think reverse splits are going to cut it